1
|
Cunha Matosinhos R, Frézard F, Mendes Silva Araújo S, Magalhães Barbosa A, de Souza IF, de Souza Filho JD, de Souza J, Corrêa Oliveira Bahia AP, Ietta F, Magnani A, Saúde-Guimarães DA. Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout. Sci Rep 2024; 14:6991. [PMID: 38523180 PMCID: PMC10961318 DOI: 10.1038/s41598-024-57663-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Accepted: 03/20/2024] [Indexed: 03/26/2024] Open
Abstract
Gout and hyperuricemia are characterized by high uric acid levels, and their treatment involves medications that have adverse effects. In this study, we evaluated oral liposomal formulations with eremantholide C and goyazensolide as a novel approach to reduce the toxicity associated with these substances while maintaining their anti-hyperuricemic activity. We characterized the formulations and evaluated them based on encapsulation efficiency and stability over 12 months and under simulated physiological environments. We determined the toxicity of the liposomal formulations in Caco-2 cells and the anti-hyperuricemic activity in rats. The formulations exhibited nanometric size, a narrow size distribution, and a negative zeta potential, indicating their stability and uniformity. The efficient encapsulation of the sesquiterpene lactones within the liposomes emphasizes their potential for sustained release and therapeutic efficacy. Stability evaluation revealed a small decrease in the eremantholide C concentration and a remarkable stability in the goyazensolide concentration. In Caco-2 cells, the liposomes did not exert toxicity, but did exhibit an antiproliferative effect. In vivo assays demonstrated that the liposomes reduced serum uric acid levels. Our study represents an advancement in gout and hyperuricemia treatment. The liposomal formulations effectively reduced the toxicity associated with the sesquiterpene lactones while maintaining their therapeutic effects.
Collapse
Affiliation(s)
- Rafaela Cunha Matosinhos
- Laboratório de Plantas Medicinais (LAPLAMED), Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, 35400-000, Brazil
| | - Frédéric Frézard
- Laboratório de Biofísica e Sistemas Nanoestruturados (LabNano), Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, 31270-901, Brazil
| | - Sabrina Mendes Silva Araújo
- Laboratório de Biofísica e Sistemas Nanoestruturados (LabNano), Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, 31270-901, Brazil
| | - Andressa Magalhães Barbosa
- Laboratório de Plantas Medicinais (LAPLAMED), Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, 35400-000, Brazil
| | - Isabela Fernanda de Souza
- Laboratório de Plantas Medicinais (LAPLAMED), Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, 35400-000, Brazil
| | - José Dias de Souza Filho
- Laboratório Multiusuário de Caracterização de Moléculas (LMCM), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, 35400-000, Brazil
| | - Jacqueline de Souza
- Laboratório de Controle de Qualidade de Insumos, Fármacos e Medicamentos (LCQ), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, 35400-000, Brazil
| | - Ana Paula Corrêa Oliveira Bahia
- Laboratório de Biofísica e Sistemas Nanoestruturados (LabNano), Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, 31270-901, Brazil
| | - Francesca Ietta
- Dipartimento Scienze della Vita, Università degli Studi di Siena, 53100, Siena, Tuscany, Italy
| | - Agnese Magnani
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, 53100, Siena, Tuscany, Italy
| | - Dênia Antunes Saúde-Guimarães
- Laboratório de Plantas Medicinais (LAPLAMED), Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, 35400-000, Brazil.
| |
Collapse
|
2
|
Guizze F, Serra CHR, Giarolla J. PAMAM Dendrimers: A Review of Methodologies Employed in Biopharmaceutical Classification. J Pharm Sci 2022; 111:2662-2673. [PMID: 35850238 DOI: 10.1016/j.xphs.2022.07.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 07/11/2022] [Accepted: 07/11/2022] [Indexed: 11/08/2022]
Abstract
The oral route is the preferred way of drug administration for most drugs, whose treatment success is directly related to the compound intestinal absorption. This absorption process, in its turn, is influenced by several factors impacting the drug bioavailability, which is extremely dependent on the maximum solubility and permeability. However, optimizing these last two factors, without chemical structural modification, is challenging. Although poly(amidoamine) dendrimers (PAMAM) are an innovative and promising strategy as drug delivery compounds, there are few studies that determine the permeability and solubility of PAMAM-drugs derivatives. Considering this scenario, this paper aimed to carry out a literature review of the last five years concerning biopharmaceutical characterizations of dendrimer delivery systems. In vitro methodologies, such as the Parallel artificial membrane permeability assay (PAMPA) (non-cellular based model) and Caco-2 cells (cellular based model), used for the permeability evaluation in the early stages of drug discovery proved to be the most promising methodologies. As a result, we discussed, for instance, that through the usage of PAMPA it was possible to evaluate the higher capacity for transdermal delivery of DNA of TAT-conjugated PAMAM, when in comparison with unmodified PAMAM dendrimer with a P<0.05. We also presented the importance of choosing the best methods of biopharmaceutical characterization, which will be essential to guarantee the efficacy and safety of the drug candidate.
Collapse
Affiliation(s)
- Felipe Guizze
- School of Pharmaceutical Sciences, Department of Pharmacy, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-000, São Paulo, Brazil
| | - Cristina Helena Reis Serra
- School of Pharmaceutical Sciences, Department of Pharmacy, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-000, São Paulo, Brazil.
| | - Jeanine Giarolla
- School of Pharmaceutical Sciences, Department of Pharmacy, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-000, São Paulo, Brazil.
| |
Collapse
|
3
|
OUP accepted manuscript. J Pharm Pharmacol 2022; 74:1140-1151. [DOI: 10.1093/jpp/rgac020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Accepted: 03/05/2022] [Indexed: 11/12/2022]
|
4
|
Porat D, Azran C, Mualem Y, Vainer E, Gibori R, Vaynshtein J, Dukhno O, Dahan A. Lamotrigine therapy in patients after bariatric surgery: Potentially hampered solubility and dissolution. Int J Pharm 2021; 612:121298. [PMID: 34793937 DOI: 10.1016/j.ijpharm.2021.121298] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 11/10/2021] [Accepted: 11/11/2021] [Indexed: 12/16/2022]
Abstract
Bariatric surgery is an effective treatment of obesity and related comorbidities. With surgery, the stomach undergoes major anatomical/physiological changes that may affect the oral exposure of drugs, especially marginally soluble weak bases, such as lamotrigine. The aim of this work was to study the solubility/dissolution of lamotrigine in conditions simulating the stomach before vs. after bariatric surgery. Lamotrigine solubility was studied in-vitro, as well as ex-vivo in gastric content aspirated from patients before vs. after bariatric surgery. We then compared the dissolution kinetics of various marketed lamotrigine products in pre- vs. post-operative stomach conditions, different in volume, pH, agitation strength and speed. Decreased lamotrigine solubility with increasing pH (from 1.37 ± 0.09 (pH = 1) to 0.22 ± 0.03 mg/mL (pH = 7)) was obtained. Twelve-fold higher lamotrigine solubility was revealed in gastric content aspirated before vs. after surgery (8.5 ± 0.7 and 0.7 ± 0.01 mg/mL, respectively). Dissolution studies showed that only the lowest dose (25 mg) fully dissolved in the post-surgery stomach conditions, while at higher doses, lamotrigine tablet dissolution was impaired. Neither fast-dissolving tablet, nor tablet crushing, helped resolving this problem. Based on these results, and given that dissolution of the drug dose governs the subsequent absorption, close monitoring of this essential drug is advised after bariatric surgery.
Collapse
Affiliation(s)
- Daniel Porat
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
| | - Carmil Azran
- Clinical Pharmacy, Herzliya Medical Center, Herzliya 46140, Israel
| | - Yoni Mualem
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
| | - Ella Vainer
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
| | - Roni Gibori
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
| | - Julie Vaynshtein
- Department of Surgery B, Soroka University Medical Center, Beer-Sheva 8410101, Israel
| | - Oleg Dukhno
- Department of Surgery B, Soroka University Medical Center, Beer-Sheva 8410101, Israel
| | - Arik Dahan
- Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
| |
Collapse
|
5
|
Sass DC, Ferreira AE, Vieira G, Rezende ALM, Kovatch PY, Palaretti V, Constantino MG, Heleno VC. Complete 1H and 13C NMR structural assignments for five semi-synthetic eremantholides. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2021.131004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Caldeira TG, Saúde-Guimarães DA, González-Álvarez I, Bermejo M, de Souza J. Eremantholide C from aerial parts of Lychnophora trichocarpha, as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination. Daru 2021; 29:195-203. [PMID: 33884588 PMCID: PMC8149492 DOI: 10.1007/s40199-021-00397-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Accepted: 04/13/2021] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Lychnophora trichocarpha (Spreng.) Spreng. ex Sch.Bip has been used in folk medicine to treat pain, inflammation, rheumatism and bruises. Eremantholide C, a sesquiterpene lactone, is one of the substances responsible for the anti-inflammatory and anti-hyperuricemic effects of L. trichocarpha. OBJECTIVES Considering the potential to become a drug for the treatment of inflammation and gouty arthritis, this study evaluated the permeability of eremantholide C using in situ intestinal perfusion in rats. From the permeability data, it was possible to predict the fraction absorbed of eremantholide C in humans and elucidate its oral absorption process. METHODS In situ intestinal perfusion studies were performed in the complete small intestine of rats using different concentrations of eremantholide C: 960 μg/ml, 96 μg/ml and 9.6 μg/ml (with and without sodium azide), in order to verify the lack of dependence on the measured permeability as a function of the substance concentration in the perfusion solutions. RESULTS Eremantholide C showed Peff values, in rats, greater than 5 × 10-5 cm/s and fraction absorbed predicted for humans greater than 85%. These results indicated the high permeability for eremantholide C. Moreover, its permeation process occurs only by passive route, because there were no statistically significant differences between the Peff values for eremantholide C. CONCLUSION The high permeability, in addition to the low solubility, indicated that eremantholide C is a biologically active substance BCS class II. The pharmacological activities, low toxicity and biopharmaceutics parameters demonstrate that eremantholide C has the necessary requirements for the development of a drug product, to be administered orally, with action on inflammation, hyperuricemia and gout.
Collapse
Affiliation(s)
- Tamires Guedes Caldeira
- Programa de Pós-graduação em Ciências Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, Minas Gerais, 35400-000, Brazil.
| | - Dênia Antunes Saúde-Guimarães
- Programa de Pós-graduação em Ciências Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, Minas Gerais, 35400-000, Brazil
| | - Isabel González-Álvarez
- Department of Engineering, Pharmaceutics and Pharmaceutical Technology Area, Universidad Miguel Hernández de Elche, Alicante, Spain
| | - Marival Bermejo
- Department of Engineering, Pharmaceutics and Pharmaceutical Technology Area, Universidad Miguel Hernández de Elche, Alicante, Spain
| | - Jacqueline de Souza
- Programa de Pós-graduação em Ciências Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, Minas Gerais, 35400-000, Brazil
| |
Collapse
|
7
|
Caldeira TG, Saúde-Guimarães DA, De Lacerda DLR, Mussel WDN, Yoshida MI, De Souza J. Polymorphic characterization and implications on biopharmaceutics properties of potential anti-inflammatory drug candidate eremantholide C from Lychnophora trichocarpha (Brazilian Arnica). J Pharm Pharmacol 2019; 71:910-919. [PMID: 30773639 DOI: 10.1111/jphp.13080] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 01/25/2019] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To perform the polymorphic and physicochemical characterization of the potential anti-inflammatory drug, eremantholide C (EREC), as well as to evaluate the influence of these characteristics on its biopharmaceutics classification. METHODS Eremantholide C was obtained from chloroformic extract of Lychnophora trichocarpha and crystallized in two distinct solvents: chloroform (EREC 1) and ethyl acetate (EREC 2). To evaluate the polymorphism, EREC samples were submitted to melting point, purity, infrared spectroscopy, differential scanning calorimetry (DSC), X-ray powder diffraction, optical microscopy and scanning electron microscopy analysis. In addition, EREC samples crystallized after intrinsic dissolution study were submitted to DSC and X-ray powder diffraction analysis. KEY FINDINGS EREC 1 showed fusion at 234.7-241.6 °C, while EREC 2 showed fusion at 238.6-243.7 °C. No polymorphic transitions were observed during the intrinsic dissolution experiment. A single sharp endothermic peak was obtained for the EREC samples. X-ray diffraction showed no crystallographic differences between the EREC samples. EREC 1 and EREC 2 showed birefringence under polarized light and indefinite morphology; however, the shape of the crystals was common to the two samples. CONCLUSIONS Eremantholide C does not present classical or morphological polymorphism; therefore, there is no influence of crystalline transitions in the solubility and consequently in its biopharmaceutics classification and oral absorption process.
Collapse
Affiliation(s)
- Tamires G Caldeira
- Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
| | | | - Dâmaris L R De Lacerda
- Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
| | - Wagner Da Nova Mussel
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Maria Irene Yoshida
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Jacqueline De Souza
- Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
| |
Collapse
|
8
|
de Camargo MS, De Grandis RA, da Silva MM, da Silva PB, Santoni MM, Eismann CE, Menegário AA, Cominetti MR, Zanelli CF, Pavan FR, Batista AA. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors. Biometals 2018; 32:89-100. [PMID: 30506342 DOI: 10.1007/s10534-018-0160-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 11/28/2018] [Indexed: 11/27/2022]
Abstract
Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anticancer agents. Previous studies showed that three ruthenium(II) compounds: [Ru(pySH)(bipy)(dppb)]PF6 (1), [Ru(HSpym)(bipy)(dppb)]PF6 (2) and Ru[(SpymMe2)(bipy)(dppb)]PF6 (3) presented anticancer properties higher than doxorubicin and cisplatin and acted as human topoisomerase IB (Topo I) inhibitors. Here, we focused our studies on in vitro intestinal permeability and anticancer mechanisms of these three complexes. Caco-2 permeation studies showed that 1 did not permeate the monolayer of intestinal cells, suggesting a lack of absorption on oral administration, while 2 and 3 permeated the cells after 60 and 120 min, respectively. Complexes 2 and 3 fully inhibited Topo II relaxation activity at 125 µM. In previously studies, 3 was the most potent inhibitor of Topo I, here, we concluded that it is a dual topoisomerase inhibitor. Moreover, it presented selectivity to cancer cells when evaluated by clonogenic assay. Thus, 3 was selected to gene expression assay front MDA-MB-231 cells from triple-negative breast cancer (TNBC), which represents the highly aggressive subgroup of breast cancers with poor prognosis. The analyses revealed changes of 27 out of 84 sought target genes. PARP1 and PARP2 were 5.29 and 1.83 times down-regulated after treatment with 3, respectively. PARPs have been attractive antitumor drug targets, considering PARP inhibition could suppress DNA damage repair and sensitize tumor cells to DNA damage agents. Recent advances in DNA repair studies have shown that an approach that causes cell lethality using synthetic PARP-inhibiting drugs has produced promising results in TNBC.
Collapse
Affiliation(s)
- Mariana S de Camargo
- Center of Exact Sciences and Technology, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil.
| | - Rone A De Grandis
- School of Pharmaceutical Sciences, São Paulo State University, Araraquara, SP, 14800-903, Brazil
| | - Monize M da Silva
- Center of Exact Sciences and Technology, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil
| | - Patricia B da Silva
- Department of Genetics and Morphology, University of Brasilia, Federal District, DF, 70910-970, Brazil
| | - Mariana M Santoni
- School of Pharmaceutical Sciences, São Paulo State University, Araraquara, SP, 14800-903, Brazil
| | - Carlos E Eismann
- Center of Environmental Studies, São Paulo State University, Rio Claro, SP, 13506-900, Brazil
| | - Amauri A Menegário
- Center of Environmental Studies, São Paulo State University, Rio Claro, SP, 13506-900, Brazil
| | - Marcia R Cominetti
- Department of Gerontology, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil
| | - Cleslei F Zanelli
- School of Pharmaceutical Sciences, São Paulo State University, Araraquara, SP, 14800-903, Brazil
| | - Fernando R Pavan
- School of Pharmaceutical Sciences, São Paulo State University, Araraquara, SP, 14800-903, Brazil
| | - Alzir A Batista
- Center of Exact Sciences and Technology, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil
| |
Collapse
|